CompletedNot Applicable

Sensory Modulation Dysfunction and Posttraumatic Stress Disorder

Israel248 participantsStarted 2023-05-01

Plain-language summary

To explore the role of sensory modulation dysfunction (SMD) (i.e., a neurodevelopmental state altering the sensory perception, severely interfering with daily function) as a risk factor for posttraumatic stress disorder (PTSD), its co-occurring pain, and impeded cognitive functions, following exposure to combat trauma.

Who can participate

Age range18 Years – 28 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Intact or corrected vision * Proficiency in Hebrew * Exclusion Criteria: * Neurological disorders * Psychiatric disorders * Neurodevelopmental disorders * Substance use disorder * Chronic pain * Regular intake of medications. * Cultural and societal backgrounds that might bias participant reaction to study protocol (i.e., nationality)

What they're measuring

Pain Sensitivity Questionnaire (PSQ)

Timeframe: Change from immediately before and immediately after the manipulation and 40 days post undertaking the manipulation

Spontaneously occurring memories

Timeframe: Change between T2, T3, T4: SpecificallyT2-during 6 days, starting the day after undertaking the experiment = trauma film paradigm, 10 (T3); and 40 (T4) days follow-up, following experimental manipulation

Trial details

NCT IDNCT05967962

SponsorTel Aviv University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Posttraumatic Stress Disorder trials